SongLi Pharmaceutical-B (01672): The small molecule GLP-1R agonist ASC30, a long-acting subcutaneous depot formulation for weight maintenance, demonstrated an apparent half-life of 75 days in obese subjects.

Zhimedia Finance APP News, GeLi Pharmaceuticals-B(01672) announced that the small molecule GLP-1 receptor agonist ASC30, a super-long-acting subcutaneous depot formulation for weight maintenance, has demonstrated an observed half-life of 75 days in obese subjects (body mass index (BMI) 30 kg/m2) in a Phase Ib clinical trial in the United States (NCT06679959). This data supports ASC30 as a maintenance therapy for long-term weight management, administered once every quarter. ASC30's weight maintenance formulation was developed using GeLi's Ultra-Long-Acting Platform (ULAP).